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Iron deficiency and iron deficiency anemia are highly prevalent inlow-income countries, especially among young children. Hepcidin isthe major regulator of systemic iron homeostasis. It controls dietary
iron absorption, dictates whether absorbed iron is made available in cir-
culation for erythropoiesis and other iron-demanding processes, and pre-
dicts response to oral iron supplementation. Understanding how hep-
cidin is itself regulated is therefore important, especially in young chil-
dren. We investigated how changes in iron-related parameters, inflam-
mation and infection status, seasonality, and growth influenced plasma
hepcidin and ferritin concentrations during infancy using longitudinal
data from two birth cohorts of infants in rural Gambia (n=114 and
n=193). This setting is characterized by extreme seasonality, prevalent
childhood anemia, undernutrition, and frequent infection. Plasma was
collected from infants at birth and at regular intervals, up to 12 months
of age. Hepcidin, ferritin and plasma iron concentrations declined
markedly during infancy, with reciprocal increases in  soluble transferrin
receptor and transferrin concentrations, indicating declining iron stores
and increasing tissue iron demand. In cross-sectional analyses at 5 and 12
months of age, we identified expected relationships of hepcidin with
iron and inflammatory markers, but also observed significant negative
associations between hepcidin and antecedent weight gain.
Correspondingly, longitudinal fixed effects modeling demonstrated
weight gain to be the most notable dynamic predictor of decreasing hep-
cidin and ferritin through infancy across both cohorts. Infants who grow
rapidly in this setting are at particular risk of depletion of iron stores, but
since hepcidin concentrations decrease with weight gain, they may also
be the most responsive to oral iron interventions.
ABSTRACT
Introduction
Iron deficiency anemia (IDA) affected 1.24 billion peo-
ple and was the most common cause of Years Lived with
Disability (YLD) in low- and low-middle income countries
in 2016.1 Iron deficiency (ID) and anemia disproportion-
ately affect young children in such socio-economic set-
tings.2 Beyond anemia, ID during infancy is linked to
impaired cognitive and behavioral development, poten-
tially yielding irreversible long-term individual and socie-
tal impacts.3,4 
Neonates are born with a maternal iron endowment
that is initially largely contained within hemoglobin and
influenced by birthweight, gestational age, and the timing
and method of cord clamping.5-7 In healthy term infants,
this birth endowment meets the iron needs of blood vol-
ume expansion, brain development and tissue accretion
for several months, compensating for the very low level of
iron in breast milk;5 after this, complementary feeding
must supply iron.6-9 Iron-poor diets and high infection bur-
dens, when combined with the significant physiological
iron demands of growth and development during infancy,
render young LMIC children especially vulnerable to
ID/IDA.
The hepatic hormone hepcidin regulates systemic iron
handling.10 Hepcidin inhibits the cellular iron exporter fer-
roportin, preventing iron recycling by erythrophagocytic
macrophages and dietary iron uptake through entero-
cytes.11 Hepcidin induction by iron prevents iron overload,
while its production during inflammation/infection gener-
ates an acute anti-infective hypoferremia;12,13 moreover,
chronically raised hepcidin causes ID and IDA,14 and
chronic ID and IDA can protect against malaria.15-17 In con-
trast, hepcidin suppression during iron demand, for exam-
ple via erythroferrone activity in response to erythropoiet-
ic stress, increases serum iron availability.18 In African pre-
school children, hepcidin reflects iron status and effective-
ly predicts utilization of orally administered iron.19,20
However, its regulation during the first year of life remains
poorly characterized.6 
The Gambia is an African country characterized by high
burdens of infection, undernutrition and anemia, together
with extreme seasonality, all of which have the potential
to influence iron control through effects on hepcidin.21 In
the clearly demarcated wet season, nutritional availability
and quality deteriorate, infections are more prevalent, and
growth faltering is more prominent. Here, we used two
longitudinal birth cohort studies from rural communities
in The Gambia to investigate how relative changes in iron,
infection and inflammation, erythropoietic drive, season-
ality, and growth rate predict changes in hepcidin and the
iron stores marker ferritin during the first year of life. 
Methods
Details of  cohort characteristics, methods and statistics are pre-
sented in the Online Supplementary Appendix and Online
Supplementary Tables S1 and S2.
Cohorts
We obtained biochemical, anthropometric and infection data at
serial time points [birth (cord blood), 2, 5, 9 (VA cohort only) and
12 months of age] from two rural birth-cohort studies in The
Gambia, West Africa:  
- VPM study: Vaccination and Paediatric Microbiome (VPM)
study. Conducted in the Western Region; March 2013-September
2015; n=114; 
- VA study: a vitamin A supplementation randomized con-
trolled trial.22 Conducted in the West Kiang Region; September
2001-October 2004; n=193. 
Laboratory analysis
Ferritin, plasma iron, soluble transferrin receptor (sTfR), α(1)-
acid glycoprotein (AGP), C-reactive protein (CRP), transferrin
(VPM only), and hemoglobin (VA only) concentrations were meas-
ured by automated analyzers. Hepcidin was measured by manual
ELISA (Bachem/Peninsula Laboratories, San Carlos, CA, USA).21  
Definitions
Anthropometric Z-scores (World Health Organization child
growth standards): generated using STATA package zscore06.23
Wet season: July-October. Weaning: first recorded occurrence of
any feeding other than exclusive breastfeeding. Positive recent
infection: occurrence within the previous four weeks of ear infec-
tion, chest infection, meningitis/sepsis, or other symptoms associ-
ated with infection (including fever, diarrhea, vomiting), or if
antibiotics were administered within the previous two weeks
(VPM); or of diarrhea, vomiting, fever, cough or clinic attendance
(VA).  Iron deficiency (ID): ferritin <12 μg/L or ferritin <30 μg/L if
CRP >5 mg/L; anemia: Hb <11 g/dL; inflammation: CRP >5 mg/L;
iron deficiency anemia (IDA): anemia in the presence of ID.21 
Statistical analysis 
RStudio (v1.1), Stata14 (Statacorp-LP), R (www.r-project.org) and
Prism7 (GraphPad Software) were used for statistical analysis and
graphics.  
To address the potential bias that may arise when deriving
parameter estimates in the presence of missing data,24,25 as dis-
cussed in detail in the Online Supplementary Appendix, we imple-
mented multiple imputation by chained equations (MICE) to gen-
erate 100 independent datasets with missing data imputed;26 after
analyzing imputed datasets, estimates were pooled using Rubin’s
rules.27 Continuous variables were log10-transformed prior to
multiple imputation. Subsequent analyses were performed on
both imputed datasets and original pre-imputation datasets; the
latter are shown in the Online Supplementary Appendix. 
Analyses comprised: 
- univariate correlations with hepcidin and ferritin, computing
Pearson correlation coefficients; 
- multivariate cross-sectional analyses at five and 12 months of
age incorporating parameters returning P<0.2 in univariate analy-
sis; Seemingly Unrelated Regression analysis,28 enabled simulta-
neous modeling of the correlated outcomes, hepcidin and ferritin; 
- longitudinal panel fixed effects models [estimating Driscoll-
Kraay standard errors29 using Stata command xtscc (st0128)30] to
enable investigation of how within-infant changes over time in
time-variant explanatory variables predict changes in hepcidin and
ferritin addressing any confounding induced by time-invariant
characteristics (e.g. sex, genotype, ethnicity), whether measured
or unmeasured; to visualize relative effect sizes, data were stan-
dardized, fixed effects models were refitted, and forest plots were
generated.
Ethical considerations  
The Gambia Government/Medical Research Council (MRC)
Joint Ethics Committee approved both studies (VPM: SCC1315;
VA: SCC844); VA was also approved by the Ethics Committee of
the London School of Hygiene and Tropical Medicine (LSHTM),
Banjul, The Gambia. All participants were recruited via approved
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protocols; parents and/or legal guardians gave written informed
consent for infants. Studies were performed in accordance with
the Declaration of Helsinki.
Results
Decline in hepcidin and iron status through infancy
High plasma concentrations of hepcidin and ferritin in
the absence of inflammation suggest that the majority of
infants were iron replete at birth and up to two months of
age (Figure 1A and B). Hepcidin concentrations declined
from two to 12 months of age in both VPM and VA infant
cohorts. In both cohorts, declines were most marked in
males born in the lower birthweight group (Figure 1A).
Similar patterns of decline were observed for ferritin, indi-
cating rapid depletion of iron stores through infancy
(Figure 1B). The decline in hepcidin and ferritin occurred
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1544 haematologica | 2019; 104(8)
Figure 1. Changes in hepcidin and iron/inflammatory biomarkers across the first year of life in Gambian infants. Plots summarize changes in (A) hepcidin, (B) fer-
ritin, (C) C-reactive protein (CRP), (D) α(1)-acid glycoprotein (AGP), (E) plasma iron, (F) soluble transferrin receptor (sTfR), and (G) transferrin (VPM only), and (H) hemo-
globin (VA cohort) occurring across the first year of life in two cohorts of Gambian infants, VPM (left panels) and VA (right panels). Plots depict mean for cross-sec-
tional data at each time point, stratifying by sex (male: blue; female:  red) and birthweight group [World Health Organization  weight-for-age z-score (WAZ) -0.5: above
-0.5: solid line, or below -0.5: dashed line], summarizing 100 datasets in which any missing data was imputed by multiple imputation, combined using Rubin’s com-
bination rules, as described in detail in the Methods section and the Online Supplementary Methods. 95% Confidence Intervals are omitted for clarity, but are given
in Online Supplementary Table S4. Equivalent plots based on the original data prior to multiple imputation are shown in Online Supplementary Figure S1.  VPM:
Vaccination and Paediatric Microbiome study; VA: a vitamin A supplementation randomized controlled trial.22
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despite higher inflammatory burden later in infancy,
reflected by increased CRP and AGP concentrations
(Figure 1C and D). Plasma iron showed the most striking
decline of any iron biomarker, with concentrations falling
from birth in all infant groups, irrespective of sex or birth-
weight, to concentrations well below normal expected
values for iron replete young children (typically >10
μmol/L)31   by five months of age in both cohorts (Figure
1E). Concentrations of sTfR, commonly used as a surro-
gate for erythropoietic iron demand, were reduced at two
months of age (until when erythropoietic output is likely
to have been low32) in both cohorts.  Erythropoietic activ-
ity typically increases from around this age, and is likely
influenced by the declining plasma iron availability; con-
sistent with this, sTfR and transferrin concentrations were
both elevated by 12 months of age, again most notably in
lower birthweight males (Figure 1F and G). Accordingly,
this group had the lowest hemoglobin concentration by
12 months of age (Figure 1H), and by this time the popu-
lation had experienced a heavy burden of iron deficiency
and anemia: 67.7% (95%CI: 56.2-79.2%) and 36.4%
(95%CI: 25.6-47.3%) of females, and 77.8% (95%CI:
65.6-90.0%) and 45.3% (95%CI: 34.5-56.1%) of males in
VPM and VA, respectively, were classified as iron deficient
at 1 year of age; 86.5% (95%CI: 79.5-93.5%) of females
and 93.1% (95%CI: 87.8-98.4%) of males were classified
as anemic in VA (in which hemoglobin was measured)
(Online Supplementary Table S3).
Associations with hepcidin and ferritin concentrations
at five and 12 months of age: cross-sectional analyses
To explore the relationships of hepcidin and ferritin
with other variables during infancy, we next performed
cross-sectional univariable analyses at month 5 (the time
Rapid growth and hepcidin suppression in infancy
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Data summarize 100 datasets in which any missing data were imputed using multiple imputation as described in detail in the Methods section and the Online Supplementary
Appendix. Infection was coded as “no infection=0” and “occurrence of infection=1’; Season was coded as “dry season (November-June)=0” and “wet season (July-October)=1”;
Sex was coded as “female=0” and “male=1”; Head Circ.: head circumference. “r” denotes the Pearson correlation coefficient. Significance level is highlighted with blue shading.
Dark blue:  P<0.001; mid-blue: P<0.01; light blue: P<0.05.
Table 1. Cross-sectional correlations between hepcidin, ferritin, and explanatory variables in infants at five months of age.
point nearest typical weaning) (Table 1) and at month 12
(Table 2). There were significant correlations in both
cohorts of hepcidin and ferritin with sTfR, transferrin
(assessed in VPM only), CRP and AGP, suggesting hep-
cidin is regulated similarly in infants compared to older
children/adults.21
Lower birthweight correlated significantly with lower
hepcidin concentrations at five and 12 months in VPM,
and at five months in VA, likely reflecting how individuals
born with smaller iron endowments are at greater risk of
iron depletion during infancy.8 However, we also found
strong evidence that the extent of antecedent weight gain
(especially weight gain between 0 and 5 months of age)
was negatively associated with the hepcidin and ferritin
concentrations observed at both five and 12 months of age
(Tables 1 and 2). In contrast, there were no significant
associations of hepcidin and ferritin concentrations at any
time point with subsequent weight gain in either cohort
(data not shown).
We then constructed multivariate models to investigate
A.E. Armitage et al.
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Table 2. Cross-sectional correlations between hepcidin, ferritin, and explanatory variables in infants at 12 months of age.
Data summarize 100 datasets in which any missing data were imputed using multiple imputation as described in detail in the Methods section and the Online Supplementary
Appendix. Infection was coded as “no infection=0” and “occurrence of infection=1’; Season was coded as “dry season (November-June)=0” and “wet season (July-October)=1”;
Sex was coded as “female=0” and “male=1”; Head Circ.: head circumference. “r” denotes the Pearson correlation coefficient. Significance level is highlighted with blue shading.
Dark blue:  P<0.001; mid-blue: P<0.01; light blue: P<0.05.
the hierarchy of factors associating with hepcidin and fer-
ritin concentrations at five and 12 months. In these mod-
els, higher weight gain since birth remained a significant
independent predictor of reduced hepcidin at five months
of age in both cohorts (Table 3), and at 12 months in VPM
(Table 4), irrespective of birthweight; however, weight
change did not associate with ferritin concentration in
these analyses. At 12 months of age,  hepcidin was posi-
tively associated with CRP and season and inversely asso-
ciated with sTfR, while at both time points and in each
cohort we found significant inverse associations of ferritin
with sTfR (Tables 3 and 4).
Together, these analyses not only highlight associations
of hepcidin with markers of erythropoietic drive, inflam-
mation and season that align with previous observations
in older African pre-school children,21 but also reveal con-
sistent evidence that prior weight gain predicts hepcidin
(although not ferritin) at key time points across these
infant populations, irrespective of birthweight and espe-
cially in earlier infancy.
Factors predicting changes in hepcidin and ferritin
over time within infants: longitudinal analysis
We then utilized the longitudinal data, fitting fixed
effects models to examine how changes over time in time-
variant parameters (sTfR, CRP, plasma iron, infections,
season, weaning status and growth) predicted changes
over time in hepcidin and ferritin within infants. Fixed
effects models eliminate confounding caused by any time-
invariant characteristic, measured or unmeasured, and
Rapid growth and hepcidin suppression in infancy
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Figure 2. The relative influence of time-variant factors on changes in hepcidin and ferritin over time during the first year of life in Gambian infants: standardized
Forest plots summarizing fixed effect models. Plots depict how a change of one standard deviation of an explanatory variable over time induces a change in standard
deviation of outcome variables hepcidin (left panels) and ferritin (right panels) over time within a child in (A) the VPM cohort and (B) the VA cohort. Outcome variables
are modeled simultaneously as “seemingly unrelated variables” to account for hepcidin/ferritin correlation, and data represent the pooled analysis of 100 datasets
in which any missing data were imputed by multiple imputation, combined using Rubin’s combination rules, as described in detail in the Online Supplementary
Methods. Weaning was defined as the first recorded occurrence of any type of feeding other than exclusive breastfeeding. sTfR: soluble transferrin receptor; CRP: C-
reactive Protein; Hb: hemoglobin. The wet season was classified as July-October. Plots depict standardized coefficients with 95% Confidence Intervals. *P<0.05;
**P<0.01; ***P<0.001. Interactions of weight change with birthweight group [above or below World Health Organization weight-for-age Z-score (WAZ) of -0.5, i.e.
close to the median observed across these two cohorts] and sex were modeled. #P<0.05; ##P<0.01; ###P<0.001; respectively, for differences in the coefficients
for weight change with respect to higher birthweight females as the reference group. Unstandardized and standardized coefficients are given in Table 5; equivalent
analysis based on the dataset prior to multiple imputation is given in Online Supplementary Table S5. MH: higher birthweight males; ML: lower birthweight males;
FH: higher birthweight females; FL: lower birthweight females; VPM: Vaccination and Paediatric Microbiome study; VA: a vitamin A supplementation randomized con-
trolled trial.22
A
B
enable estimation of within-child effects, contrasting the
above cross-sectional models. Moreover, standardizing
coefficients allows comparison of the relative effect sizes
of explanatory variables on outcome variables (Tables 5
and 6 and Figure 2).
Infection and increases in CRP over time associated
with increasing hepcidin, while rising sTfR predicted hep-
cidin decline within infants, suggesting the models cap-
tured effects on hepcidin in expected directions. Increased
plasma iron over time associated with decreased hepcidin
in both cohorts. In the VPM dataset, the transition from
dry to wet season, when infections are more prevalent,
also associated with increased hepcidin (Table 5 and
Figure 2A).
However, consistent with the cross-sectional (i.e.
between-infant) analyses, the dynamic predictor of hep-
cidin decline that had the largest effect size in fixed effects
models (i.e. within-infant) in both cohorts was weight
gain (Tables 5 and 6 and Figure 2). The effect of weight
gain on hepcidin suppression was highly significant in all
groups of infants but was most pronounced in males: that
is, a given increase in weight had a stronger suppressive
effect on hepcidin over time in males (especially those
born in the lower birthweight group in VPM) than in
females. Weight gain also significantly predicted ferritin
decline in both cohorts (in contrast to the multivariate
cross-sectional analyses at 5 and 12 months). The effect of
weight gain on ferritin decline, like hepcidin, was larger in
males in the VPM cohort (Table 5 and Figure 2A) although
no sex difference on ferritin was observed in the VA
cohort.
Discussion
Hepcidin is the key regulator of iron absorption and dic-
tates whether absorbed iron is sequestered or made avail-
able in the circulation.10  Understanding how hepcidin is
regulated is therefore vital in understanding the differen-
tial drivers of iron status, and how and whether iron inter-
ventions aimed at combating ID might be effectively tar-
geted.6 Here, we have taken advantage of serial sampling
of infants from two Gambian cohorts to describe changes
in hepcidin and ferritin levels during the first year of life,
and to examine how they are influenced by different fac-
tors using both cross-sectional and time series analysis.
A.E. Armitage et al.
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Table 3. Cross-sectional multivariate associations between hepcidin, ferritin and explanatory variables in infants at five months of age. 
A. VPM – 5 months – N=114                                       Coefficient                                     95% CI                                                          P
Outcome variable: HEPCIDIN                                                                                                                                                                                                       
Plasma iron, µmol/L                                                                   -0.127                                            -0.252 – -0.002                                                             0.047
sTfR, mg/L                                                                                    -0.641                                            -1.592 – 0.310                                                             0.186
CRP, mg/L                                                                                       0.218                                             -0.076 – 0.513                                                             0.145
Infection in last 4 weeks                                                           0.103                                             -0.144 – 0.350                                                             0.412
Sex                                                                                                 -0.050                                            -0.238 – 0.139                                                             0.606
Weight change (0-5 months), kg                                             -5.543                                            -8.786 – -2.300                                                             0.001
Season                                                                                           0.247                                              0.080 – 0.413                                                              0.004
Outcome variable: FERRITIN                                                                                                                                                                                                        
sTfR, mg/L                                                                                    -1.076                                             -2.11 – -0.039                                                              0.042
CRP, mg/L                                                                                       0.265                                             -0.043 – 0.574                                                             0.092
Sex                                                                                                 -0.251                                            -0.463 – -0.039                                                             0.020
Weight change (0-5 months), kg                                             -1.828                                            -0.463 – 1.607                                                             0.297
B. VA – 5 months – N=193                                          Coefficient                                     95% CI                                                          P
Outcome variable: HEPCIDIN                                                                                                                                                                                                       
sTfR, mg/L                                                                                    -0.700                                            -1.362 – -0.039                                                             0.039
CRP, mg/L                                                                                       0.148                                              0.033 – 0.263                                                              0.012 
Infection in last 4 weeks                                                           -0.054                                            -0.283 – 0.175                                                             0.645
Weight change (0-5 months), kg                                             -3.307                                            -6.069 – -0.545                                                             0.019
Outcome variable: FERRITIN                                                                                                                                                                                                        
Plasma iron, µmol/L                                                                    0.057                                             -0.129 – 0.244                                                             0.545
sTfR, mg/L                                                                                    -1.127                                            -1.953 – -0.301                                                             0.008
CRP, mg/L                                                                                      -0.031                                            -0.175 – 0.113                                                             0.670
Hb, g/dL                                                                                          1.627                                             -1.000 – 4.253                                                             0.224
Sex                                                                                                 -0.066                                            -0.347 – 0.216                                                             0.648
Weight change (0-5 months), kg                                             -0.173                                            -4.364 – 4.018                                                             0.935
The outcome variables hepcidin and ferritin were handled using Seemingly Unrelated Regressions, with World Health Organization birth weight-for-age Z-score used as an instru-
ment for weight change. Only variables with P<0.2 in univariate regressions were included in multivariable models, omitting correlated indices as described in the Methods sec-
tion. Data summarise 100 datasets in which any missing data were imputed using multiple imputation as described in detail in the Methods section and the Online Supplementary
Appendix. Infection was coded as “no infection=0” and “occurrence of infection=1’; Season was coded as “dry season (November-June)=0” and “wet season (July-October)=1”;
Sex was coded as “female=0” and “male=1”.
We demonstrate that a marked decline in iron status
through infancy is reflected by progressive reduction in
hepcidin concentrations, and that while hepcidin appears
to be regulated by similar factors in infants, older children
and adults, weight gain is the most prominent dynamic
predictor of the extent of hepcidin decline in infants. The
data highlight post-natal growth as being strongly associ-
ated with the onset of iron depletion, and potentially asso-
ciated with downstream sequelae, including anemia in
vulnerable populations of infants.
The decline of hepcidin during infancy observed in both
cohorts is consistent with data from previous smaller
studies in Zimbabwean and Kenyan infants,33-35 which
likewise described more pronounced effects in males. The
parallel declines in hepcidin and ferritin, at a time when
inflammation (which would be expected to increase both
markers) is rising, illustrate the rapidity and severity of the
onset of ID. Contrasting the dynamics of hepcidin in
African infants, hepcidin levels were reported as stable
during the first year in Europeans,36,37 presumably reflect-
ing higher iron provision in weaning diets and lower
cumulative exposure to infection and consequent inflam-
mation. Human breastmilk has a low iron content5 and
Gambian babies are predominantly breastfed for the first
6 months and beyond.38  Moreover, as our data demon-
strate, inflammation, infection and the season when infec-
tions are more prevalent were all associated with relative-
ly raised hepcidin concentrations, even in cases of low
iron status, potentially contributing to iron depletion in
African infants.
One notable observation was the dramatic depletion of
plasma iron between birth and 5 months of age to concen-
trations well below the previously described typical levels
in infancy;31 these low levels persisted throughout the
remainder of the first year. Availability of plasma iron  is
critical for supplying iron-demanding tissues. During
infancy, iron is essential for erythropoiesis, but is also
required by the developing brain which is a key consumer
of iron,4 as well as by muscle and for tissue accretion.39
The proportional iron demands of these tissues are not
constant through the first year of life: for example, ery-
thropoietin levels and erythropoietic output are relatively
low in neonates,32  despite early infancy being a period of
rapid growth. Effective adaptive immunity, critical in
LMIC infants, also requires iron; this is demonstrated by
the recent discovery that a mutation in the Tfrc gene
Rapid growth and hepcidin suppression in infancy
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Table 4. Cross-sectional multivariate associations between hepcidin, ferritin and explanatory variables in infants at five months of age. 
A. VPM – 12 months – N=114                                  Coefficient                                          95% CI                                                           P
Outcome variable: HEPCIDIN                                                                                                                                                                                                           
sTfR, mg/L                                                                                -1.708                                                  -2.568 – -0.849                                                             <0.001
CRP, mg/L                                                                                  0.221                                                     0.100 – 0.342                                                               <0.001
Infection in last 4 weeks                                                       0.167                                                    -0.068 – 0.401                                                                0.163
Weight change (0-12 months), kg                                      -2.833                                                   -5.583 – 0.082                                                                0.044
Season                                                                                       0.343                                                     0.104 – 0.582                                                                0.005
FERRITIN                                                                                                                                                                                                                                               
sTfR, mg/L                                                                                -1.200                                                  -2.225 – -0.175                                                               0.022
CRP, mg/L                                                                                  0.170                                                     0.001 – 0.339                                                                0.049
Infection in last 4 weeks                                                       0.223                                                    -0.089 – 0.537                                                                0.161
Sex                                                                                             -0.247                                                   -0.535 – 0.040                                                                0.091
B. VA – 12 months – N=193                                     Coefficient                                          95% CI                                                           P
Outcome variable: HEPCIDIN                                                                                                                                                                                                           
sTfR, mg/L                                                                                -1.191                                                  -1.870 – -0.511                                                               0.001
CRP, mg/L                                                                                  0.163                                                     0.040 – 0.286                                                                0.009
Hb, g/dL                                                                                     0.330                                                    -1.784 – 2.443                                                                0.760
Sex                                                                                             -0.287                                                  -0.485 – -0.089                                                               0.005
Weight change (0-12 months), kg                                      -1.362                                                   -4.298 – 1.574                                                                0.363
Season                                                                                       0.267                                                     0.081 – 0.453                                                                0.005
Outcome variable: FERRITIN                                                                                                                                                                                                            
sTfR, mg/L                                                                                -1.450                                                  -2.095 – -0.805                                                             <0.001
CRP, mg/L                                                                                  0.109                                                    -0.016 – 0.234                                                                0.087
Hb, g/dL                                                                                     0.275                                                    -1.844 – 2.395                                                                0.799
Sex                                                                                             -0.055                                                   -0.243 – 0.132                                                                0.562
Weight change (0-12 months), kg                                      -1.325                                                   -4.168 – 1.518                                                                0.361
Season                                                                                       0.112                                                    -0.077 – 0.301                                                                0.247
The outcome variables hepcidin and ferritin were handled using Seemingly Unrelated Regressions, with World Health Organization birth weight-for-age Z-score used as an instru-
ment for weight change. Only variables with P<0.2 in univariate regressions were included in multivariable models, omitting correlated indices as described in the Methods sec-
tion. Data summarize 100 datasets in which any missing data were imputed using multiple imputation as described in detail in the Methods section and the Online Supplementary
Appendix. Infection was coded as “no infection=0” and “occurrence of infection=1’; Season was coded as “dry season (November-June)=0” and “wet season (July-October)=1”;
Sex was coded as “female=0” and “male=1”.
(encoding transferrin receptor 1, TfR1), which abrogated
lymphocyte iron acquisition, was the cause of fatal com-
bined immunodeficiency due to an inability to protect
against infections.40 Thus, it is conceivable that low plas-
ma iron availability may similarly impair adaptive immu-
nity. The longitudinal analyses paradoxically suggested
that changes in plasma iron inversely predicted changes in
hepcidin; the reason for this is unclear, but could be driven
by events in the first two months, when serum iron and
hepcidin appear to differ most in their kinetics.
Soluble transferrin receptor is frequently used as a bio-
marker of tissue iron demand, and is typically associated
with erythropoiesis.41 Concentrations of sTfR fell between
birth and two months of age in both cohorts, presumably
reflecting low erythropoietic demand at this point conse-
quent upon the decline of the high birth hemoglobin con-
centration and recycling of its iron; however, sTfR concen-
trations were raised by 12 months of age, especially in
males. By this time, elevated sTfR strongly associated
with suppressed hepcidin, and fixed effects modeling,
demonstrated how increases in sTfR within an infant over
time predicted hepcidin reduction (overcoming the hep-
cidin-stimulatory effect of inflammation). Erythropoietic
drive can suppress liver hepcidin production through
activity of the recently characterized erythroblast-derived
hormone erythroferrone, liberating iron to meet erythro-
poietic demands. 18Erythroferrone assays were not avail-
able at the time of this analysis, but it will be important to
investigate its role during infancy, especially in LMIC set-
tings.  In addition, our cross-sectional and longitudinal
analyses both also revealed weight gain to be strongly
associated with declining hepcidin during infancy. Tissue
accretion and erythropoietic expansion are widely
acknowledged as consumers of iron in infancy, yet vari-
ability in growth rate within and between infants is less
frequently considered to be a risk factor for earlier onset of
iron depletion and deficiency in infancy than other risk
factors (such as premature birth, early cord clamping, low
birthweight or early consumption of cow’s milk).6,9 In uni-
variable analysis, lower birthweight did correlate as
expected with reduced hepcidin at five months in both
cohorts, yet there was more consistent evidence of a rela-
tionship between antecedent growth and hepcidin (noting
that there was no such relationship of hepcidin or ferritin
with subsequent weight gain); moreover, in multivariate
cross-sectional models, prior weight gain remained signif-
icantly inversely associated with hepcidin, irrespective of
birthweight. Our longitudinal fixed effects models added
strength to these observations, with more rapid weight
gain predicting a more profound decline in hepcidin over
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1550 haematologica | 2019; 104(8)
Table 5. The relative influence of time-variant factors on changes in hepcidin and ferritin over time during the first year of life in Gambian infants:
fixed effect models – VPM cohort.
Variable                                                       Coefficient                        95% CI                    Coefficient                  95% CI                             P
                                                               (unstandardized)           (unstandardized)         (standardized)         (standardized)                         
Outcome variable: HEPCIDIN                                                                                                                                                                                                                 
Season                                                                           0.106                              0.013 – 0.200                         0.092                      0.011 – 0.172                            0.026
Infection in last 4 weeks                                           0.207                              0.119 – 0.294                         0.141                      0.081 – 0.202                          <0.001
Weaning                                                                        -0.060                            -0.165 – 0.046                        -0.047                     -0.131 – 0.037                           0.265
Plasma iron, µmol/L                                                   -0.080                            -0.150 – -0.010                       -0.108                    -0.202 – -0.015                          0.025
sTfR, mg/L                                                                    -0.974                            -1.206 – -0.741                       -0.328                    -0.407 – -0.248                         <0.001
CRP, mg/L                                                                       0.105                              0.042 – 0.168                         0.145                      0.059 – 0.231                            0.001
Weight, kg                                                                     -1.402                            -1.786 – -1.018                       -0.411                    -0.522 – -0.301                         <0.001
lower birthweight females                                     -0.281                            -0.687 – 0.125                        -0.083                     -0.202 – 0.037                           0.172
lower birthweight males                                         -1.064                            -1.781 – -0.348                       -0.312                    -0.520 – -0.104                          0.005
higher birthweight males                                       -0.313                            -0.628 – 0.002                        -0.092                     -0.184 – 0.000                           0.052
Outcome variable: FERRITIN                                                                                                                                                                                                                  
Season                                                                           0.104                              0.033 – 0.176                         0.065                      0.020 – 0.110                            0.005
Infection in last 4 weeks                                           0.085                             -0.000 – 0.171                         0.042                      -0.000 – 0.085                           0.050
Weaning                                                                        -0.438                            -0.586 – -0.291                       -0.251                    -0.337 – -0.166                         <0.001
Plasma iron, µmol/L                                                   -0.048                            -0.124 – 0.028                        -0.047                     -0.121 – 0.028                           0.215
sTfR, mg/L                                                                    -1.176                            -1.439 – -0.914                       -0.286                    -0.349 – -0.223                         <0.001
CRP, mg/L                                                                       0.069                              0.017 – 0.120                         0.068                      0.017 – 0.120                            0.010
Weight, kg                                                                     -1.760                            -2.144 – -1.377                       -0.374                    -0.455 – -0.293                         <0.001
lower birthweight females                                     -0.099                            -0.559 – 0.361                        -0.021                     -0.119 – 0.077                           0.672
lower birthweight males                                        -0.626                            -1.080 – -0.172                       -0.133                    -0.229 – -0.037                          0.007
higher birthweight males                                       -0.966                            -1.560 – -0.371                       -0.205                    -0.331 – -0.079                          0.002
Data represent the pooled analysis of 100 datasets in which any missing data were imputed by multiple imputation, combined using Rubin’s combination rules, as described
in detail in Online Supplementary Methods. Unstandardized coefficients indicate the effect of a unit change over time of an explanatory variable on changes over time within
a child in the outcome variables hepcidin and ferritin, which were handled using seemingly unrelated regression to account for strong correlations between outcome variables.
Standardized coefficients indicate the effect of a change of one standard deviation of an explanatory variable over time on standard deviation of outcome variables over time
within a child. Infection was coded as “no infection=0” and “occurrence of infection=1”; Season was coded as “dry season (November-June)=0” and “wet season (July-
October)=1”; Sex was coded as “female=0” and “male=1”. Interactions of weight change with birthweight group (groups indicated in italics: above or below WHO weight-for-age
z-score of -0.5) and sex were modeled with coefficients/P-values representing differences for weight change relative to higher birthweight females as reference group. 
time. In the within-subject analyses, there was also a high-
ly significant effect of weight gain on ferritin decline,
apparently contrasting the cross-sectional models in
which no association of ferritin with weight gain was
found; this discrepancy likely reflects the better efficiency
of analyzing data longitudinally. 
The hepcidin-suppressive effect of rapid growth there-
fore warrants mechanistic evaluation. It may relate to
known hepcidin-regulatory signals, such as decreased
transferrin saturation and hepatic iron. Growth factors,
especially insulin-like growth factor 1 (IGF-1), play impor-
tant roles in infant growth and development;42 hepatocyte
growth factor (HGF), epidermal growth factor (EGF), and
platelet-derived growth factor BB (PDGF-BB) are able to
down-regulate hepcidin transcription.43,44 These or related
growth factors should, therefore, be considered as candi-
date contributors to hepcidin suppression during infancy.
Furthermore, erythroferrone provides a precedent for an
iron-demanding process, erythropoiesis, evolving to pro-
duce a hepcidin suppressive hormone to facilitate iron
supply. Further consideration should be given to the
extent to which decreasing transferrin saturation due to,
or erythroferrone derived from, an expanding erythron
accounts for the observed relationship between rapid
growth and hepcidin suppression and iron depletion at
different stages of infancy, compared to growth and devel-
opment of other tissues such as muscle and brain.
Whether non-erythroid iron-demanding tissues that grow
rapidly during infancy similarly up-regulate erythrofer-
rone itself or other, as yet undefined, signals should be
investigated. 
The proportional effect of weight gain on hepcidin was
also more pronounced in males. This sex difference might
reflect differences in hormonal regulation of hepcidin
exacerbating effects of weight gain: for example, testos-
terone suppresses hepcidin in mice45  and humans,46 and is
elevated in males during the 'mini-puberty' of early infan-
cy.47 
The availability of two well-sized cohorts providing
longitudinal data provides a key strength of the analyses
presented here, allowing investigation of factors affecting
changes in hepcidin and ferritin within infants through the
first year. Causal inference using longitudinal data faces
two sources of confounding: time-variant confounding
and time-invariant confounding. Unlike other regression
models, fixed effects panel models control for any time-
invariant confounding, measured or unmeasured. Despite
this benefit, our models are still unlikely to fully capture
all potential time-variant explanatory variables, limiting
inference of causation. Since our analyses were retrospec-
Rapid growth and hepcidin suppression in infancy
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Table 6. The relative influence of time-variant factors on changes in hepcidin and ferritin over time during the first year of life in Gambian infants:
fixed effect models – VA cohort.
Variable                                                      Coefficient                         95% CI                    Coefficient                    95% CI                            P
                                                              (unstandardized)            (unstandardized)           (standardized)            (standardized)                         
Outcome variable:HEPCIDIN                                                                                                                                                                                                                     
Season                                                                          0.063                              -0.040 – 0.166                          0.038                        -0.024 – 0.100                           0.231
Infection in last 4 weeks                                          0.116                               0.009 – 0.224                          0.072                         0.005 – 0.140                           0.035
Plasma iron, µmol/L                                                 -0.194                             -0.342 – -0.466                        -0.204                       -0.356 – -0.052                          0.009
sTfR, mg/L                                                                   -1.161                             -1.513 – -0.809                        -0.316                       -0.406 – -0.225                        <0.001
CRP, mg/L                                                                     0.133                               0.060 – 0.205                          0.160                         0.073 – 0.246                          <0.001
Hb, g/dL                                                                        0.115                              -0.610 – 0.840                          0.012                        -0.061 – 0.084                           0.751
Weight, kg                                                                   -1.581                             -2.342 – -0.819                        -0.347                       -0.516 – -0.179                        <0.001
lower birthweight females                                    -0.484                             -1.083 – 0.116                         -0.106                        -0.238 – 0.026                           0.112
ower birthweight males                                        -0.745                             -1.229 – -0.260                        -0.163                       -0.270 – -0.057                          0.003
higher birthweight males                                      -1.226                             -1.819 – -0.633                        -0.269                       -0.398 – -0.140                        <0.001
Outcome variable: FERRITIN                                                                                                                                                                                                                     
Season                                                                         -0.044                             -0.154 – 0.065                        -0.024                        -0.085 – 0.036                           0.425
Infection in last 4 weeks                                          0.073                              -0.078 – 0.225                          0.042                        -0.045 – 0.129                           0.338
Plasma iron, µmol/L                                                 -0.008                             -0.137 – 0.120                         -0.008                        -0.132 – 0.115                           0.895
sTfR, mg/L                                                                   -1.762                             -2.205 – -1.319                        -0.442                       -0.552 – -0.332                        <0.001
CRP, mg/L                                                                     0.014                              -0.048 – 0.076                          0.016                        -0.053 – 0.084                           0.651
Hb, g/dL                                                                       -0.158                             -1.354 – 1.037                         -0.015                        -0.126 – 0.096                           0.792
Weight, kg                                                                   -2.278                             -3.165 – -1.391                        -0.461                       -0.641 – -0.281                        <0.001
lower birthweight females                                    0.273                              -0.494 – 1.039                          0.055                        -0.100 – 0.211                           0.481
lower birthweight males                                        0.254                              -0.606 – 1.115                          0.051                        -0.122 – 0.225                           0.558
higher birthweight males                                      -0.164                             -1.011 – 0.683                         -0.033                        -0.205 – 0.139                           0.700
Data represent the pooled analysis of 100 datasets in which any missing data were imputed by multiple imputation, combined using Rubin’s combination rules, as described
in detail in Online Supplementary Methods. Unstandardized coefficients indicate the effect of a unit change over time of an explanatory variable on changes over time within
a child in the outcome variables hepcidin and ferritin, which were handled using seemingly unrelated regression to account for strong correlations between outcome variables.
Standardized coefficients indicate the effect of a change of one standard deviation of an explanatory variable over time on standard deviation of outcome variables over time
within a child. Infection was coded as “no infection=0” and “occurrence of infection=1’; Season was coded as “dry season (November-June)=0” and “wet season (July-
October)=1”; Sex was coded as “female=0” and “male=1”. Interactions of weight change with birthweight group (groups indicated in italics: above or below WHO weight-for-age
z-score of -0.5) and sex were modeled with coefficients/P-values representing differences for weight change relative to higher birthweight females as reference group. 
tive investigations of cohorts that had been enrolled for
other purposes, certain desirable variables were unavail-
able: for example, hemoglobin data were not collected in
VPM, and for both cohorts, we cannot exclude the possi-
bility  that participants took iron-containing supplements,
breast-milk substitutes or fortified complementary diets
during the study period since this information was not
systematically collected. Furthermore, given the known
impact of season on iron status in this region,21 it would
have been desirable for enrollment to span at least one full
year in each cohort. This was not the case in VPM, mean-
ing the majority of VPM 12-month samples were taken in
the dry season (Online Supplementary Table S2A), possibly
explaining in part the apparent higher prevalence of ID in
VPM at 12 months (Online Supplementary Table S3).
Nevertheless, we believe our models are still of great value
in characterizing predictors of hepcidin and ferritin decline
in infancy.
Other limitations should also be considered. Self-report-
ing of infectious episodes may have poor sensitivity and
specificity for actual infection. Plasma biomarkers of
inflammation may only capture current or recent inflam-
matory insults; since previous inflammation may con-
tribute to reduced iron status through chronically raised
hepcidin, higher resolution tracking of inflammatory
events between key time points would be desirable.
Finally, whether the effects we describe are maintained in
distinct LMIC infant populations, most notably regions
with a high malarial burden, should be further investigat-
ed.
Universal iron interventions for LMIC infants have
proven to be relatively ineffective in reducing the burden
of anemia, partly because only a proportion of anemia is
thought to be iron responsive.48 Iron absorption is facili-
tated in the presence of low hepcidin concentrations, but
inhibited when hepcidin is raised (such as during infec-
tion/inflammation), potentially explaining why many
infants respond poorly to iron interventions.20,49,50 Growth
rate has previously been linked to reduced ferritin and iron
deficiency,51-54  and has been shown to be predictive of
hemoglobin response to iron supplementation;55 hepcidin
suppression during rapid growth likely explains the latter
effect. Since rapid growth predicts greater hepcidin sup-
pression, our data suggest that simple weight monitoring
could enable identification of rapidly growing infants to
whom oral iron might be advantageously targeted.  
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